ADMA Biologics refutes allegations

ADMA Biologics has issued a statement strongly refuting allegations made by short seller Culper Research, characterizing them as unsubstantiated, misleading, and inaccurate. The company asserts that the research firm's assessment of ADMA's business and its late-line therapy role demonstrates a blatant misunderstanding. This public rebuttal aims to correct the market's perception and defend the company's position.